Interleukin-36 promotes systemic Type-I IFN responses in severe psoriasis.
Marika Catapano, Marta Vergnano, Marco Romano, Satveer K Mahil, Siew-Eng Choon, David A Burden, Helen S Young, Ian M Carr, Helen J Lachmann, Giovanna Lombardi, Catherine Smith, Francesca D Ciccarelli, Jonathan N Barker, Francesca Capon
The paper identifies an IL-36/TLR-9/Type-I IFN axis that drives systemic inflammation in psoriasis, offering a potential therapeutic target.
bioRxiv · Dec 14, 2018 · PreprintImmunology